177Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?

  • Kambiz Rahbar
  • Hojjat Ahmadzadehfar
  • Martin Boegemann
Letter to the Editor
  • 395 Downloads

Notes

Compliance with ethical standards

Disclosure

The University of Münster received consulting fees from ABX Advanced Biochemical Compounds, Radeberg, Germany, for KR and MB. The authors declare they have no conflicts of interest according to the subject and matter of the presented article.

Conflict of interest

The authors declare that they have no financial or non-financial competing interests.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.

References

  1. 1.
    Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schafers M, Essler M, et al. German multicenter study investigating 177Lu-PSMA-617 Radioligand therapy in advanced prostate cancer patients. J Nucl Med. 2017;58(1):85–90.CrossRefPubMedGoogle Scholar
  2. 2.
    Hofman MS, Sandhu S, Eu P, Price J, Akhrust T, Iravani A, et al. Lutetium-177 PSMA (LuPSMA) theranostics phase II trial: efficacy, safety and QoL in patients with castrate-resistant prostate cancer treated with LuPSMA. Ann Oncol. 2017;28(Suppl 5).Google Scholar
  3. 3.
    Rahbar K, Boegemann M, Yordanova A, Eveslage M, Schafers M, Essler M, et al. PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival. Eur J Nucl Med Mol Imaging. 2017.Google Scholar
  4. 4.
    Smith M, De Bono J, Sternberg C, Le Moulec S, Oudard S, De Giorgi U, et al. Phase III study of Cabozantinib in previously treated metastatic castration-resistant prostate cancer: COMET-1. J Clin Oncol. 2016;34(25):3005–13.CrossRefPubMedGoogle Scholar
  5. 5.
    Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol. 2016;34(12):1402–18.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2017

Authors and Affiliations

  1. 1.Department of Nuclear MedicineUniversity Hospital MuensterMünsterGermany
  2. 2.Department of Nuclear MedicineUniversity Hospital BonnBonnGermany
  3. 3.Department of UrologyUniversity Hospital MuensterMünsterGermany

Personalised recommendations